BioSpace News Archive

This week, Diabetes Advocates from around the country gathered in D.C. for the American Diabetes Association’s Call to Congress, an annual gathering on Capitol Hill to educate members of Congress about the impacts of diabetes and advocate for key federal priorities.

Sometimes your joy is the source of your smile,” opines Zen master Thích Nhất Hạnh. “But sometimes your smile can be the source of your joy.

Moberg Pharma AB has completed the divestment of its OTC-business to RoundTable Healthcare Partners and Signet Healthcare Partners for USD 155 million.

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of American Renal Associates Holdings, Inc. between August 10, 2016 and March 27, 2019, both dates inclusive.

The U.S. Food and Drug Administration approved Mavenclad tablets to treat relapsing forms of multiple sclerosis in adults, to include relapsing-remitting disease and active secondary progressive disease.

On March 27, 2019, ThermoLife International, LLC filed suit in Arizona Federal District Court against Olympus Labs. ThermoLife’s Complaint brings claims against Olympus Labs for false advertising under 25 U.S.C. § 1125(d), false marking under 35 U.S.C. § 292 and unfair competition.

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company developing novel therapeutics for global markets, today announced the completion of the first part of the single ascending dose (SAD) study testing the intravenous formulation of the first-in-class therapeutic antibody ASLAN004 in healthy volunteers.

Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has raised $11.5 million in a Series B funding round led by Mirae Asset Venture Investment and Mirae Asset Capital.

Applied DNA to Receive Staged Payments Totaling $5M Over the Next Four-Months

IDEAYA Biosciences, Inc. announced that Novartis will present a poster with data from an ongoing clinical trial evaluating the tolerability and preliminary clinical activity of IDE196 as a potential monotherapy in metastatic uveal melanoma.